Affimed N.V.
AFMDQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.1K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16,100.00 |
|---|---|
| Enterprise Value | $6.12 Million |
| Earnings per Share | $-7.09 |
| Beta | 0.28 |
| Outstanding Shares | 16,100,185 |
Return
| Return on Equity | -406.92% |
|---|---|
| Return on Assets | -175.10% |
| Return on Invested Capital | -304.65% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 6.98 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.21 |
| Debt to Equity | 0.79 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 3, 2026
EPS Estimate
$-0.42
Consensus analyst estimateRevenue Estimate
$175,141
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.43
Consensus analyst estimateRevenue Estimate
$170,867
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Affimed N.V.
76 employees
CEO: Shawn Leland
Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13,...